{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:07:25Z","timestamp":1781003245645,"version":"3.54.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004052","name":"King Abdullah University of Science and Technology","doi-asserted-by":"crossref","award":["OSR-NTGC-2021-4587"],"award-info":[{"award-number":["OSR-NTGC-2021-4587"]}],"id":[{"id":"10.13039\/501100004052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44645-8","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:14:13Z","timestamp":1774253653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heterologous saRNA prime \u2013 multivalent protein boost strategy induces broad and durable immunity against SARS-CoV-2 and MERS-CoV"],"prefix":"10.1038","volume":"16","author":[{"given":"Dominik","family":"Renn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine S.","family":"McPartlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Banala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulami","family":"Talukder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Mandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Eppinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasdave S.","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Rueping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"2","key":"44645_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41423-023-01116-8","volume":"21","author":"S Cankat","year":"2024","unstructured":"Cankat, S., Demael, M. U. & Swadling, L. In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. Cell Mol. Immunol. 21 (2), 103\u2013118 (2024).","journal-title":"Cell Mol. Immunol."},{"issue":"1","key":"44645_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41541-025-01156-3","volume":"10","author":"LA Bruno","year":"2025","unstructured":"Bruno, L. A. et al. Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity. npj Vaccines. 10 (1), 108 (2025).","journal-title":"npj Vaccines"},{"issue":"8","key":"44645_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3390\/vaccines13080797","volume":"13","author":"J Kim","year":"2025","unstructured":"Kim, J. et al. Adjuvanted protein vaccines boost RNA-based vaccines for broader and more potent immune responses. Vaccines 13 (8), 797 (2025).","journal-title":"Vaccines"},{"issue":"10","key":"44645_CR4","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.7150\/ijbs.45472","volume":"16","author":"ZW Ye","year":"2020","unstructured":"Ye, Z. W. et al. Zoonotic origins of human coronaviruses. Int. J. Biol. Sci. 16 (10), 1686\u20131697 (2020).","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"44645_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.anai.2020.11.021","volume":"126","author":"M Fung","year":"2021","unstructured":"Fung, M., Otani, I., Pham, M. & Babik, J. Zoonotic coronavirus epidemics: severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019. Ann. Allergy Asthma Immunol. 126 (4), 321\u2013337 (2021).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"44645_CR6","doi-asserted-by":"crossref","unstructured":"Kane, Y., Wong, G., Gao, G. F. & Models, A. Zoonotic reservoirs, and cross-species transmission of emerging human-infecting coronaviruses. Annu. Rev. Anim. Biosci. 11, 1\u201331 (2023).","DOI":"10.1146\/annurev-animal-020420-025011"},{"issue":"3","key":"44645_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17 (3), 181\u2013192 (2019).","journal-title":"Nat. Rev. Microbiol."},{"issue":"5","key":"44645_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41579-021-00652-2","volume":"20","author":"M Ruiz-Aravena","year":"2022","unstructured":"Ruiz-Aravena, M. et al. Ecology, evolution and spillover of coronaviruses from bats. Nat. Rev. Microbiol. 20 (5), 299\u2013314 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"44645_CR9","doi-asserted-by":"crossref","unstructured":"Almaghaslah, D., Kandasamy, G., Almanasef, M., Vasudevan, R. & Chandramohan, S. Review on the coronavirus disease (COVID-19) pandemic: Its outbreak and current status. Int. J. Clin. Pract. 74 (11), e13637 (2020).","DOI":"10.1111\/ijcp.13637"},{"key":"44645_CR10","doi-asserted-by":"crossref","unstructured":"Polato\u011flu, I., Oncu-Oner, T., Dalman, I. & Ozdogan, S. COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies. MedComm  4 (2), e228 (2023).","DOI":"10.1002\/mco2.228"},{"issue":"3","key":"44645_CR11","doi-asserted-by":"publisher","first-page":"227990362311863","DOI":"10.1177\/22799036231186349","volume":"12","author":"M Kapoor","year":"2023","unstructured":"Kapoor, M., Nidhi Kaur, K., Saeed, S., Shannawaz, M. & Chandra, A. Impact of COVID-19 on healthcare system in India: a systematic review. J. Public. Health Res. 12 (3), 22799036231186349 (2023).","journal-title":"J. Public. Health Res."},{"key":"44645_CR12","doi-asserted-by":"publisher","first-page":"1114085","DOI":"10.3389\/fpubh.2023.1114085","volume":"11","author":"R Xu","year":"2023","unstructured":"Xu, R. et al. Evaluation of the impact of the COVID-19 pandemic on health service utilization in China: a study using auto-regressive integrated moving average model. Front. Public. Health. 11, 1114085 (2023).","journal-title":"Front. Public. Health"},{"issue":"8","key":"44645_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1056\/NEJMe2001126","volume":"382","author":"S Perlman","year":"2020","unstructured":"Perlman, S. & Decade, A. Another coronavirus. N. Engl. J. Med. 382 (8), 760\u2013762 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"44645_CR14","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.3390\/v6082991","volume":"6","author":"R McBride","year":"2014","unstructured":"McBride, R., van Zyl, M. & Fielding, B. C. The coronavirus nucleocapsid is a multifunctional protein. Viruses 6 (8), 2991\u20133018 (2014).","journal-title":"Viruses"},{"key":"44645_CR15","unstructured":"WHO Middle East respiratory syndrome coronavirus (MERS-CoV). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/middle-east-respiratory-syndrome-coronavirus-(mers-cov) (2023)."},{"key":"44645_CR16","unstructured":"WHO Middle East respiratory syndrome coronavirus -. Kingdom of Saudi Arabia. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON560 (2025)."},{"key":"44645_CR17","unstructured":"FOA Animal health MERS-CoV situation update. https:\/\/www.fao.org\/animal-health\/situation-updates\/mers-coronavirus (2025)."},{"issue":"3","key":"44645_CR18","doi-asserted-by":"publisher","first-page":"104111","DOI":"10.1016\/j.lpm.2022.104111","volume":"51","author":"P Berche","year":"2022","unstructured":"Berche, P. The enigma of the 1889 Russian flu pandemic: a coronavirus? La. Presse M\u00e9d. 51 (3), 104111 (2022).","journal-title":"La. Presse M\u00e9d."},{"key":"44645_CR19","doi-asserted-by":"crossref","unstructured":"Romano, G., Ferrari, A. & Baldanti, F. Phylogenetic and epidemiological insights into centenarians\u2019 resilience to COVID-19: exploring the role of past coronavirus pandemics. Front. Microbiol. 16, 2025 (2025).","DOI":"10.3389\/fmicb.2025.1572763"},{"issue":"2","key":"44645_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/microorganisms11020445","volume":"11","author":"CM Harrison","year":"2023","unstructured":"Harrison, C. M. et al. Evaluating the virology and evolution of seasonal human coronaviruses associated with the common cold in the COVID-19 era. Microorganisms 11 (2), 445 (2023).","journal-title":"Microorganisms"},{"key":"44645_CR21","doi-asserted-by":"crossref","unstructured":"Frutos, R., Serra-Cobo, J., Pinault, L., Lopez Roig, M. & Devaux, C. A. Emergence of bat-related betacoronaviruses: hazard and risks. Front. Microbiol. 12, 2021 (2021).","DOI":"10.3389\/fmicb.2021.591535"},{"issue":"5","key":"44645_CR22","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","volume":"176","author":"AC Walls","year":"2019","unstructured":"Walls, A. C. et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell 176 (5), 1026\u20131039e15 (2019).","journal-title":"Cell"},{"issue":"9","key":"44645_CR23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang, Y., Yang, C., Xu, X., Xu, W. & Liu, S. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 41 (9), 1141\u20131149 (2020).","journal-title":"Acta Pharmacol. Sin."},{"key":"44645_CR24","doi-asserted-by":"publisher","first-page":"205873842110501","DOI":"10.1177\/20587384211050199","volume":"35","author":"GA S\u00e1nchez-Zuno","year":"2021","unstructured":"S\u00e1nchez-Zuno, G. A. et al. A review: antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. Int. J. ImmunoPathol. Pharmacol. 35, 20587384211050199 (2021).","journal-title":"Int. J. ImmunoPathol. Pharmacol."},{"issue":"3","key":"44645_CR25","doi-asserted-by":"publisher","first-page":"105464","DOI":"10.1016\/j.micinf.2024.105464","volume":"27","author":"JM Coish","year":"2025","unstructured":"Coish, J. M., MacNeil, L. A. & MacNeil, A. J. The SARS-CoV-2 antibody-dependent enhancement fa\u00e7ade. Microbes Infect. 27 (3), 105464 (2025).","journal-title":"Microbes Infect."},{"issue":"631","key":"44645_CR26","doi-asserted-by":"publisher","first-page":"eabj6824","DOI":"10.1126\/scitranslmed.abj6824","volume":"14","author":"C Riou","year":"2022","unstructured":"Riou, C. et al. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. Sci. Transl. Med. 14 (631), eabj6824 (2022).","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"44645_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"JS Tregoning","year":"2021","unstructured":"Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21 (10), 626\u2013636 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"44645_CR28","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New Engl. J. Med. (2020)."},{"issue":"10277","key":"44645_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397 (10277), 881\u2013891 (2021).","journal-title":"Lancet"},{"issue":"10316","key":"44645_CR30","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 398 (10316), 2093\u20132100 (2021).","journal-title":"Lancet"},{"issue":"10286","key":"44645_CR31","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","volume":"397","author":"VJ Hall","year":"2021","unstructured":"Hall, V. J. et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 397 (10286), 1725\u20131735 (2021).","journal-title":"Lancet"},{"key":"44645_CR32","doi-asserted-by":"crossref","unstructured":"Vanderslott, S. et al. Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom. BMJ Glob. Health 6 (10), e006305 (2021).","DOI":"10.1136\/bmjgh-2021-006305"},{"issue":"1","key":"44645_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/22221751.2021.1902245","volume":"10","author":"Q He","year":"2021","unstructured":"He, Q. et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg. Microbes Infections. 10 (1), 629\u2013637 (2021).","journal-title":"Emerg. Microbes Infections"},{"issue":"10289","key":"44645_CR34","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","volume":"397","author":"RH Shaw","year":"2021","unstructured":"Shaw, R. H. et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet 397 (10289), 2043\u20132046 (2021).","journal-title":"Lancet"},{"key":"44645_CR35","doi-asserted-by":"publisher","first-page":"112650","DOI":"10.1016\/j.biopha.2022.112650","volume":"147","author":"TT Nguyen","year":"2022","unstructured":"Nguyen, T. T. et al. Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine. Biomed. Pharmacother. 147, 112650 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"44645_CR36","doi-asserted-by":"crossref","unstructured":"M\u00fcller-Hilke, B., Mai, F., M\u00fcller, M., Volzke, J. & Reisinger, E. C. Higher SARS-CoV-2 spike binding antibody levels and neutralization capacity 6 months after heterologous vaccination with AZD1222 and BNT162b2. Vaccines (Basel) 10, 2 (2022).","DOI":"10.3390\/vaccines10020322"},{"key":"44645_CR37","doi-asserted-by":"crossref","unstructured":"Zhu, F. et al. Safety and immunogenicity of a recombinant adenovirus type-5\u2013vectored coronavirus disease 2019 (COVID-19) vaccine with a homologous prime-boost regimen in healthy participants aged\u2009\u2265\u20096 Years: a randomized, double-blind, placebo-controlled, phase 2b trial. Clin. Infect. Dis. 2021, ciab845 (2021).","DOI":"10.1093\/cid\/ciab845"},{"issue":"4","key":"44645_CR38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","volume":"22","author":"G Zeng","year":"2022","unstructured":"Zeng, G. et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet. Infect. Dis. 22 (4), 483\u2013495 (2022).","journal-title":"Lancet. Infect. Dis"},{"issue":"10324","key":"44645_CR39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","volume":"399","author":"SA Costa Clemens","year":"2022","unstructured":"Costa Clemens, S. A. et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399 (10324), 521\u2013529 (2022).","journal-title":"Lancet"},{"issue":"2","key":"44645_CR40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-021-01677-z","volume":"28","author":"J Li","year":"2022","unstructured":"Li, J. et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat. Med. 28 (2), 401\u2013409 (2022).","journal-title":"Nat. Med."},{"issue":"14","key":"44645_CR41","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1056\/NEJMc2200415","volume":"386","author":"FB Mayr","year":"2022","unstructured":"Mayr, F. B., Talisa, V. B., Shaikh, O., Yende, S. & Butt, A. A. Effectiveness of homologous or heterologous Covid-19 boosters in veterans. N. Engl. J. Med. 386 (14), 1375\u20131377 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"44645_CR42","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/s41467-022-29219-2","volume":"13","author":"V Pavot","year":"2022","unstructured":"Pavot, V. et al. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. Nat. Commun. 13 (1), 1699 (2022).","journal-title":"Nat. Commun."},{"issue":"1","key":"44645_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41541-024-00838-8","volume":"9","author":"L Marcos-Villar","year":"2024","unstructured":"Marcos-Villar, L. et al. Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium. npj Vaccines. 9 (1), 53 (2024).","journal-title":"npj Vaccines"},{"issue":"1","key":"44645_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41541-022-00511-y","volume":"7","author":"MS Gebre","year":"2022","unstructured":"Gebre, M. S. et al. mRNA vaccines induce rapid antibody responses in mice. npj Vaccines. 7 (1), 88 (2022).","journal-title":"npj Vaccines"},{"issue":"7","key":"44645_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19 (7), 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"issue":"9","key":"44645_CR46","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction. Nat. Biotechnol. 38 (9), 1073\u20131078 (2020).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"44645_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.imlet.2012.06.002","volume":"147","author":"TR Ghimire","year":"2012","unstructured":"Ghimire, T. R., Benson, R. A., Garside, P. & Brewer, J. M. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol. Lett. 147 (1), 55\u201362 (2012).","journal-title":"Immunol. Lett."},{"key":"44645_CR48","doi-asserted-by":"crossref","unstructured":"Pedersen, G. K., W\u00f8rzner, K., Andersen, P. & Christensen, D. Vaccine adjuvants differentially affect kinetics of antibody and germinal center responses. Front. Immunol. 11, 2020 (2020).","DOI":"10.3389\/fimmu.2020.579761"},{"key":"44645_CR49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, 10 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"8","key":"44645_CR50","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.3390\/ijms23084205","volume":"23","author":"J Korbecki","year":"2022","unstructured":"Korbecki, J. et al. The importance of CXCL1 in physiology and noncancerous diseases of bone, bone marrow, muscle and the nervous system. Int. J. Mol. Sci. 23 (8), 4205 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"44645_CR51","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1517\/14728222.2013.837886","volume":"17","author":"RE Marques","year":"2013","unstructured":"Marques, R. E., Guabiraba, R., Russo, R. C. & Teixeira, M. M. Targeting CCL5 in inflammation. Expert Opin. Ther. Targets. 17 (12), 1439\u20131460 (2013).","journal-title":"Expert Opin. Ther. Targets"},{"issue":"11","key":"44645_CR52","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke, R., Hogan, M. J., Lor\u00e9, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55 (11), 1993\u20132005 (2022).","journal-title":"Immunity"},{"issue":"12","key":"44645_CR53","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/nm.3985","volume":"21","author":"VD Menachery","year":"2015","unstructured":"Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21 (12), 1508\u20131513 (2015).","journal-title":"Nat. Med."},{"issue":"1","key":"44645_CR54","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41541-022-00442-8","volume":"7","author":"ADT Barrett","year":"2022","unstructured":"Barrett, A. D. T. et al. The rapid progress in COVID vaccine development and implementation. npj Vaccines. 7 (1), 20 (2022).","journal-title":"npj Vaccines"},{"issue":"7830","key":"44645_CR55","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer, F. SARS-CoV-2 vaccines in development. Nature 586 (7830), 516\u2013527 (2020).","journal-title":"Nature"},{"issue":"6530","key":"44645_CR56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1126\/science.abe6522","volume":"371","author":"JS Lavine","year":"2021","unstructured":"Lavine, J. S., Bjornstad, O. N. & Antia, R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science 371 (6530), 741\u2013745 (2021).","journal-title":"Science"},{"key":"44645_CR57","doi-asserted-by":"crossref","unstructured":"Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595 (7868), 572\u2013577 (2021).","DOI":"10.1038\/s41586-021-03653-6"},{"issue":"58","key":"44645_CR58","doi-asserted-by":"publisher","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","volume":"6","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals after mRNA vaccination. Sci. Immunol. 6 (58), eabi6950 (2021).","journal-title":"Sci. Immunol."},{"issue":"23","key":"44645_CR59","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med. 384 (23), 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"44645_CR60","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1186\/s13256-024-04889-2","volume":"18","author":"H Hirano","year":"2024","unstructured":"Hirano, H. & Asada, H. Exponential decline, ceiling effect, downregulation, and T-cell response in immunoglobulin G antibody levels after messenger RNA vaccine boosters: a case report. J. Med. Case Rep. 18 (1), 631 (2024).","journal-title":"J. Med. Case Rep."},{"issue":"29","key":"44645_CR61","doi-asserted-by":"publisher","first-page":"e2205784119","DOI":"10.1073\/pnas.2205784119","volume":"119","author":"M Yuan","year":"2022","unstructured":"Yuan, M. et al. A broad and potent neutralization epitope in SARS-related coronaviruses. Proc. Natl. Acad. Sci. 119 (29), e2205784119 (2022).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6606","key":"44645_CR62","doi-asserted-by":"publisher","first-page":"eabq0839","DOI":"10.1126\/science.abq0839","volume":"377","author":"AA Cohen","year":"2022","unstructured":"Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377 (6606), eabq0839 (2022).","journal-title":"Science"},{"key":"44645_CR63","doi-asserted-by":"crossref","unstructured":"Pasquevich, K. A. et al. Laboratorio Pablo Cassar\u00e1, C. M. C. f. A. C., Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults. Nat. Commun. 14 (1), 4551 (2023).","DOI":"10.1101\/2023.01.10.22284009"},{"issue":"21","key":"44645_CR64","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1016\/j.cell.2021.09.015","volume":"184","author":"AC Walls","year":"2021","unstructured":"Walls, A. C. et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 184 (21), 5432\u20135447e16 (2021).","journal-title":"Cell"},{"issue":"4","key":"44645_CR65","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nri2510","volume":"9","author":"P Marrack","year":"2009","unstructured":"Marrack, P., McKee, A. S. & Munks, M. W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9 (4), 287\u2013293 (2009).","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"44645_CR66","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19 (12), 1597\u20131608 (2013).","journal-title":"Nat. Med."},{"issue":"12","key":"44645_CR67","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen, S. et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24 (12), 103479 (2021).","journal-title":"iScience"},{"issue":"6","key":"44645_CR68","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.ymthe.2022.04.011","volume":"30","author":"SM Moghimi","year":"2022","unstructured":"Moghimi, S. M. & Simberg, D. Pro-inflammatory concerns with lipid nanoparticles. Mol. Ther. 30 (6), 2109\u20132110 (2022).","journal-title":"Mol. Ther."},{"issue":"11","key":"44645_CR69","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1056\/NEJMc2110716","volume":"385","author":"J Normark","year":"2021","unstructured":"Normark, J. et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. N. Engl. J. Med. 385 (11), 1049\u20131051 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"44645_CR70","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12916-024-03471-3","volume":"22","author":"MA Asante","year":"2024","unstructured":"Asante, M. A. et al. Heterologous versus homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMC Med. 22 (1), 263 (2024).","journal-title":"BMC Med."},{"issue":"11","key":"44645_CR71","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discovery. 20 (11), 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"1","key":"44645_CR72","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.pep.2005.02.004","volume":"42","author":"X Zuo","year":"2005","unstructured":"Zuo, X. et al. Expression and purification of SARS coronavirus proteins using SUMO-fusions. Protein Expr. Purif. 42 (1), 100\u2013110 (2005).","journal-title":"Protein Expr. Purif."},{"issue":"39","key":"44645_CR73","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.3748\/wjg.v11.i39.6159","volume":"11","author":"J Chen","year":"2005","unstructured":"Chen, J. et al. Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization. World J. Gastroenterol. 11 (39), 6159\u20136164 (2005).","journal-title":"World J. Gastroenterol."},{"key":"44645_CR74","unstructured":"European Medicines Agency (EMA). Guideline on clinical evaluation of vaccines \u2013 Revision 1 (effective 01\/08\/2023). https:\/\/www.ema.europa.eu\/en\/clinical-evaluation-new-vaccines-scientific-guideline (2023)."},{"key":"44645_CR75","unstructured":"European Medicines Agency (EMA). Zabdeno EPAR. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zabdeno (2025)."},{"issue":"1","key":"44645_CR76","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis, N. C., L\u00f3pez-Cort\u00e9s, A., Gonz\u00e1lez, E. V., Grimaldos, A. B. & Prado, E. O. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. 6 (1), 28 (2021).","journal-title":"npj Vaccines"},{"key":"44645_CR77","doi-asserted-by":"crossref","unstructured":"Monteil, V. et al. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. EMBO Mol. Med. 14 (8), e15230 (2022).","DOI":"10.15252\/emmm.202115230"},{"issue":"2","key":"44645_CR78","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic. Clin. Pharm. 7 (2), 27\u201331 (2016).","journal-title":"J. Basic. Clin. Pharm."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44645-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44645-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44645-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:03:16Z","timestamp":1778425396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44645-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44645"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44645-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.T., J.S.M., C.W.M., and J.S.C. are employees of Tiba Biotech LLC and have equity interests. Tiba Biotech has filed a patent on the MDNP RNA delivery system (patent application PCT\/US21\/25542), naming P.T. and J.S.C. as inventors. J.S.C. is also an inventor on U.S. Patent no. 10,548,959 entitled \u201cCompositions and Methods for Modified Dendrimer Nanoparticle Delivery.\u201d C.W.M. has worked as a freelance consultant advising commercial and nonprofit organizations working in the fields of vaccines and viral vectors. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14565"}}